Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | CNR1 | P21554 | 2/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1222862 | 0.98 | LMNA (0.52) | LMNAKDM4ECNR1ADRA1ATDP1 | |
| Methyl Alcohol SCHEMBL28137239 | 0.98 | LMNA (0.52) | LMNAKDM4ECNR1ADRA1ATDP1 | |
| SCHEMBL1222755 | 0.98 | LMNA (0.52) | LMNAKDM4ECNR1ADRA1ATDP1 | |
| SCHEMBL2346969 | 0.98 | LMNA (0.52) | LMNAKDM4ECNR1ADRA1ATDP1 | |
| SCHEMBL1223599 | 0.98 | LMNA (0.52) | LMNAKDM4ECNR1ADRA1ATDP1 | |
| SCHEMBL7912193 | 0.92 | LMNA (0.56) | LMNAKDM4ECNR1ADRA1ATDP1 | |
| SCHEMBL28308123 | 0.91 | LMNA (0.46) | LMNAKDM4ECNR1ADRA1ATDP1 | |
| SCHEMBL8975153 | 0.91 | LMNA (0.70) | LMNAKDM4ECNR1ADRA1ATDP1 | |
| SCHEMBL16628357 | 0.89 | LMNA (0.67) | LMNAKDM4ECNR1ADRA1ATDP1 | |
| SCHEMBL9620151 | 0.89 | LMNA (0.67) | LMNAKDM4ECNR1ADRA1ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110044938-A1 | TETRAHYDROBENZOTHIOPHENE DERIVATIVES | NYCOMED GMBH (DE) | 2011-02-24 | — | — | US | disclosed |
| US-20100285149-A1 | NOVEL TETRAHYDROPYRIDOTHIOPHENES | 4SC AG (DE) | 2010-11-11 | — | — | US | disclosed |
| US-7608723-B2 | N-(3-aminopropyl)-N-[(1R)-1-(1-benzyl-1H-benzimidazol-2-yl)-2-methylpropyl]-4-chlorobenzamide;kinesin spindle protein modulators; anticarcinogenic agents; in vivo stability, bio-availability; diagnosis/medical/;antitumor agents hyperplasia; restinosis; antiinflammatory agents; cardiac hypertrophy | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| EP-2051974-A1 | TETRAHYDROBENZOTHIOPHENE DERIVATIVES | 4SC AG (DE) | 2009-04-29 | — | — | EP | disclosed |
| EP-2051983-A1 | NTETRAHYDROPYRIDOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF CANCER | 4SC AG (DE) | 2009-04-29 | — | — | EP | disclosed |
| WO-2008020045-A1 | TETRAHYDROBENZOTHIOPHENE DERIVATIVES | 4SC AG (DE) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020024-A1 | NTETRAHYDROPYRIDOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF CANCER | 4SC AG (DE) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100285149-A1 | NOVEL TETRAHYDROPYRIDOTHIOPHENES | BAX, CCAR2, BCL2 | LMNA 3689/4885KDM4E 1608/4885CNR1 2475/4885 |
| US-20110044938-A1 | TETRAHYDROBENZOTHIOPHENE DERIVATIVES | BAX, BCL2, BAD | LMNA 3666/4885KDM4E 2054/4885CNR1 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.